News and Announcements
Kinesis partners with Etheralabs
- Published August 21, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Kinesis is a digital currency backed one to one in gold and silver that aims to bring the gold standard of a monetary system onto the blockchain.
- Kinesis recently partnered with New York-based Blockchain Venture Accelerator Etheralabs.
- Etheralabs invests, builds, and deploys disruptive technologies across the Blockchain Ecosystem.
Kinesis is a digital currency backed one to one in gold and silver that aims to bring the gold standard of a monetary system onto the blockchain. In their pre-sale ITO, Kinesis sold around $15M tokens to date.
Kinesis recently partnered with New York-based Blockchain Venture Accelerator Etheralabs. Etheralab’s mission is to accelerate companies and drive engagement to world-changing ideas. The company invests, builds, and deploys disruptive technologies across the Blockchain Ecosystem.
Etheralabs has an acceleration model that is an intelligence platform of people, networks, artificial intelligence and code with over 30 years of experience and over $200 million in investment.
If you would like more information about the progression of Kinesis, click the register interest button below.
About Kinesis Money
The vision for Kinesis is to deliver an evolutionary step beyond any monetary system available today. This is achieved by basing the Kinesis currencies 1:1 on allocated physical gold and silver. Use is incentivised by attaching a unique yield system to the Kinesis currencies and distributing back the wealth generated according to proportionate currency holdings and velocity.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
